Efficacy and Safety of Paclitaxel-Based PD-1/PD-L1 Immunotherapies for Triple-Negative Breast Cancer: A Systematic Review and Network Meta-Analysis DOI Creative Commons
Youran Dai, Tao Ruan, Wenhui Yang

и другие.

Clinical Medicine Insights Oncology, Год журнала: 2024, Номер 18

Опубликована: Янв. 1, 2024

Background: Triple negative breast cancer (TNBC) is a deadly subtype of with limited treatment options. Currently, programmed death 1 (PD-1)/programmed ligand (PD-L1) inhibitors have become the first choice for immunotherapies. Despite paclitaxel being considered cornerstone drug in treatment, effectiveness, safety, and optimal selection its combination PD-1/PD-L1 remain uncertain. Methods: We conducted systematic review network meta-analysis, performing comprehensive literature search across PubMed, Embase, Cochrane Library from inception each database through May 18, 2024. Selected trials were those that assessed efficacy safety paclitaxel-based therapies TNBC. The primary endpoint was overall survival (OS), while secondary outcomes included progression-free (PFS), adverse events (AEs), response rate (ORR), Pathological complete (pCR). This study registered PROSPERO under registration number CRD42023429651. Results: A total 8 RCTs meeting our eligibility criteria included, involving 4626 patients who received either Paclitaxel (Paclitaxel-placebo/chemotherapy) or durvalumab, pembrolizumab, atezolizumab, toripalimab paclitaxel. pooled results demonstrated Durvalumab combined significantly reduced hazard ratio OS (surface cumulative ranking [SUCRA]: 91.05%) PFS compared alone (SUCRA: 83.52%). Additionally, plus improved ORR (odds [OR]: 2.30; 95% credible interval [CrI]: 1.10–5.20). For outcomes, Atezolizumab showed favorable profile AEs, no significant differences observed between groups. In pCR study, Pembrolizumab most effective option 81.85%). Conclusions: When paclitaxel, exhibit benefit. represents option. future, attention should be paid to TNBC subtypes dosage, as these factors may help design personalized programs.

Язык: Английский

Decoding male breast cancer: epidemiological insights, cutting-edge treatments, and future perspectives DOI Creative Commons
Леи Жао, H. L. Cheng,

Dongqiang He

и другие.

Discover Oncology, Год журнала: 2025, Номер 16(1)

Опубликована: Март 19, 2025

Breast cancer is predominantly recognized as a condition affecting women, however, male breast (MBC), despite its rarity, represents significant and serious malignancy in men. Accounting for approximately 1% of all cases, MBC often diagnosed at later stage compared to female cancer, primarily due lack awareness the absence screening programs tailored This delayed diagnosis typically results poorer prognoses more limited treatment options. Over past decade, there has been notable increase research surrounding MBC. surge largely driven by recognition unique epidemiological biological characteristics, which are distinct from those cancer. However, low incidence, many aspects MBC, including etiology, clinical presentation, optimal strategies, remain inadequately understood. paper aims provide comprehensive review examining mortality rates, characteristics on global scale. Additionally, it explores economic burden associated with disease, identifies key risk factors, discusses current preventive measures. Finally, will offer insights into future directions potential advancements

Язык: Английский

Процитировано

0
Comprehensive Analysis of Predictors and Outcomes in Breast Cancer Screening in Romania: Insights from Demographic, Clinical, and Lifestyle Factors DOI Open Access

Oana Maria Burciu,

Ioan Sas,

Adrian-Grigore Merce

и другие.

Journal of Clinical Medicine, Год журнала: 2025, Номер 14(5), С. 1415 - 1415

Опубликована: Фев. 20, 2025

Background/Objectives: The primary purpose of this study is to provide a more in-depth insight into various demographic, clinical, and lifestyle factors in relation breast cancer predict the extent which certain variables described as “predictors” might lead further investigation. By analyzing large cohort, we are able valuable up-to-date information on screening, support specialists, enhance international screening guidelines. Methods: We screened for population women aged 50 69 years by using standardized imaging method (breast mammography) ultrasonography complementary imagistic tool, compared results with gold standard, biopsy. For this, 58,760 no known history coming from 4 major regions Romania (North-East, North-West, South-East, West) were first evaluated through mammography. Out these, 3197 positive mammograms subsequently underwent ultrasound examination. remaining 688 patients referred Results: statistical analysis revealed several predictors such body mass index (BMI), family medical cancer, age at birth, menopause that influenced progression mammography (first stage program) towards echography (additional modality). Furthermore, established age, BMI significant biopsy (the last program). number biopsies (688) out total (58,760), calculated detection rate 8 per 1000 patients. Lastly, studying patient demographics context (BC) observed participants an urban environment presented higher mammographic ones rural provenience. Conclusions: Our analyzed cohort offers real world data shows multiple positively associated increased risk BC. Older older menopausal all estrogen-dependent linked our study. findings concerning rural/urban disparities regional differences highlight need region-specific interventions address factors, improve healthcare access, follow-up protocols, particularly underserved areas like North-East South-East regions.

Язык: Английский

Процитировано

0
Predictors of Recurrence and Overall Survival in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Surgery: A Comprehensive Statistical Analysis DOI Open Access

Vlad Bogdan Varzaru,

Roxana Popescu,

Daliborca Cristina Vlad

и другие.

Cancers, Год журнала: 2025, Номер 17(6), С. 924 - 924

Опубликована: Март 8, 2025

Background/Objectives: This study evaluates the impact of clinical, pathological, and treatment-related factors on breast cancer recurrence overall survival following neoadjuvant chemotherapy surgery. Patients Method: A total 298 patients treated at Diakoneo Diak Klinikum, Schwäbisch Hall, Germany (2010–2021) were analyzed. Key variables included hormone receptor status, molecular subtypes, tumor grade, treatment protocols, metastatic disease diagnosis. Results: Recurrence was strongly associated with (p < 0.001) but not status or subtypes. Platinum/taxane-based linked to a lower risk = 0.05) compared anthracycline-based regimens. had significantly (27.91% vs. 8.24%, p 0.001). Logistic regression suggested trend toward increased in ER-positive PR-negative patients, though statistically significant. These findings emphasize importance personalized strategies highlight need for future studies incorporating genomic data residual analysis refine prediction therapy selection.

Язык: Английский

Процитировано

0
Comprehensive Analysis of Receptor Status, Histopathological Classifications (B1–B5), and Cumulative Histological Dimensions in Breast Cancer: Predictors of Malignancy and Diagnostic Implications DOI Open Access

Oana Maria Burciu,

Ioan Sas,

Adrian-Grigore Merce

и другие.

Cancers, Год журнала: 2024, Номер 16(20), С. 3471 - 3471

Опубликована: Окт. 14, 2024

Breast cancer has become one of the most serious and widespread public health concerns globally, affecting an increasing number women-and, in rare cases, men-across world. It is common among women across all countries. In this study, we aimed to evaluate influence demographic factors, medical reproductive history, diagnostic techniques, hormone receptor status on development progression breast cancer.

Язык: Английский

Процитировано

1
Efficacy and Safety of Paclitaxel-Based PD-1/PD-L1 Immunotherapies for Triple-Negative Breast Cancer: A Systematic Review and Network Meta-Analysis DOI Creative Commons
Youran Dai, Tao Ruan, Wenhui Yang

и другие.

Clinical Medicine Insights Oncology, Год журнала: 2024, Номер 18

Опубликована: Янв. 1, 2024

Background: Triple negative breast cancer (TNBC) is a deadly subtype of with limited treatment options. Currently, programmed death 1 (PD-1)/programmed ligand (PD-L1) inhibitors have become the first choice for immunotherapies. Despite paclitaxel being considered cornerstone drug in treatment, effectiveness, safety, and optimal selection its combination PD-1/PD-L1 remain uncertain. Methods: We conducted systematic review network meta-analysis, performing comprehensive literature search across PubMed, Embase, Cochrane Library from inception each database through May 18, 2024. Selected trials were those that assessed efficacy safety paclitaxel-based therapies TNBC. The primary endpoint was overall survival (OS), while secondary outcomes included progression-free (PFS), adverse events (AEs), response rate (ORR), Pathological complete (pCR). This study registered PROSPERO under registration number CRD42023429651. Results: A total 8 RCTs meeting our eligibility criteria included, involving 4626 patients who received either Paclitaxel (Paclitaxel-placebo/chemotherapy) or durvalumab, pembrolizumab, atezolizumab, toripalimab paclitaxel. pooled results demonstrated Durvalumab combined significantly reduced hazard ratio OS (surface cumulative ranking [SUCRA]: 91.05%) PFS compared alone (SUCRA: 83.52%). Additionally, plus improved ORR (odds [OR]: 2.30; 95% credible interval [CrI]: 1.10–5.20). For outcomes, Atezolizumab showed favorable profile AEs, no significant differences observed between groups. In pCR study, Pembrolizumab most effective option 81.85%). Conclusions: When paclitaxel, exhibit benefit. represents option. future, attention should be paid to TNBC subtypes dosage, as these factors may help design personalized programs.

Язык: Английский

Процитировано

0